Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
Retrieved on:
星期四, 八月 5, 2021
Clinical trial, NK, Dove Medical Press, U.S. Securities and Exchange Commission, Mouse, Industry, Private Securities Litigation Reform Act, CD19, Risk, Biology, Security (finance), IND, Cancer, Securities Act of 1933, Triple-negative breast cancer, Patient, Imugene, File, Securities Exchange Act of 1934, Communication, Instituto de Biologia Molecular e Celular, Sale, SEC, Immune system, Vivo, Neoplasm, Confederation of Ethiopian Labor Unions, Central African Republic, Nasdaq, Prostate, Lymphoid leukemia, Terminology, 3D ultrasound, Safety, Head, Marketing, Neck, Vaccine, Pharmaceutical industry
They did this successfully in triple-negative breast, pancreatic, prostate, ovarian, head and neck, and brain cancer cell lines.
Key Points:
- They did this successfully in triple-negative breast, pancreatic, prostate, ovarian, head and neck, and brain cancer cell lines.
- CF33-CD19 oncolytic virus was then combined with CD19 CAR T cells in vitro and in vivo mice studies.
- Researchers showed significant activity with mice being cured of their cancer with the CF33-CD19 and CAR T-cell combination, as well as prolonged protective anti-tumor immunity.
- The first clinical trial is anticipated to start in 2022 and will evaluate the safety and efficacy of CF33-CD19 in combination with CAR T therapy in patients with solid tumors.